[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación para la Investigación Biosanitaria del Principado de Asturias\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640544","digital-patient-reported-assessment-in-older-adults-with-acute-leukemia-100640544",false,"NCT07597590","Digital Patient-Reported Assessment in Older Adults With Acute Leukemia","Feasibility of a Structured Digital Patient-Reported Assessment Pathway in Older Adults With Acute Leukemia: A Prospective Single-Center Pilot Study","Inclusion Criteria:\n\n* Age 65 years or older.\n* Confirmed diagnosis of acute leukemia of myeloid or lymphoid origin.\n* Active ambulatory follow-up in the Hematology Service at Hospital Universitario Central de Asturias.\n* Ability to understand the questionnaires and provide their own responses, independently or with practical assistance from a caregiver.\n* Access to a compatible internet-enabled digital device, either personally or through a caregiver.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Cognitive impairment that, in the treating hematologist's clinical judgment, prevents the participant from understanding the questionnaires or providing their own responses, despite permitted practical assistance from a caregiver.\n* Clinical condition that, in the treating hematologist's judgment, precludes completion of the study procedures.\n* Persistent inability to access or use the MiAsturSalud\u002FSESPA platform despite reasonable technical support.","ALL","65 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot study will evaluate the feasibility of implementing a structured digital patient-reported assessment pathway in adults aged 65 years or older with acute leukemia. Following activation of the institutional MiAsturSalud\u002FSESPA platform, participants will complete the EORTC QLQ-C30 and FACT-Leu remotely after the baseline visit and will repeat the digital assessment at 3-6 months. The primary outcome will be completion of at least 80% of the baseline digital assessment within 7 days. Secondary outcomes will be caregiver assistance requirement, non-completion of the planned digital follow-up assessment, and elapsed completion time. The study is not designed to establish clinical efficacy.",[26,27],"Leukemia Acute Myeloid","Leukemia Acute Lymphoid Leukemia (ALL)",[29,30,31,32,33],"acute leukemia","older adults","feasibility study","electronic patient-reported outcomes","digital health implementation","NOT_YET_RECRUITING","2026-08-04",{"date":37,"type":38},"2026-08-06","ACTUAL",{"date":40,"type":20},"2026-12",{"date":42,"type":20},"2028-06",{"name":44,"class":45},"Fundación para la Investigación Biosanitaria del Principado de Asturias","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100537762","early-transcatheter-mitral-valve-repair-after-myocardial-infarction-100537762","NCT06282042","Early Transcatheter Mitral Valve Repair After Myocardial Infarction","EMCAMI","Inclusion Criteria:\n\n* Patients with symptomatic moderate to severe or severe MR after acute MI\n* Age \\> 18 years\n* Based on the following classification recently published in \"Transcatheter Mitral Edge-to-Edge Repair for Treatment of Acute Mitral Regurgitation\" by M. Shuvy et al. (Can J Cardiol. 2023) patients will be included if categorized in Type 2, 3 or 4:\n\nExclusion Criteria:\n\n* Primary MR (e.g. papillary muscle rupture)\n* EF ≤ 25%\n* Accepted for CABG\n* Presence of cardiogenic shock (AMR type 1)","18 Years","99 Years",{"count":57,"type":20},250,[23],"To explore the impact of early transcatheter edge-to-edge repair of acute functional mitral regurgitation after myocardial infarction on the combined incidence of death and heart-failure associated hospitalisations at one-year follow-up, and quality of life and LV remodelling at two-year follow-up.",[61],"Acute Mitral Regurgitation",[63],"MitraClip","RECRUITING","2025-10-15",{"date":67,"type":38},"2025-10-20",{"date":69,"type":38},"2024-12-24",{"date":71,"type":20},"2028-06-16",{"name":44,"class":45},32,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100563317","transfusion-in-lower-risk-mds-patients-predictors-of-adequacy-of-transfusion-and-quality-of-life-in-lower-risk-mds-100563317","NCT06614595","Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS","Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life Changes","MDS-QUAL","Subjects must meet all of the following inclusion criteria:\n\n1. They must be able to understand the study procedures, comply with them, and consent in writing prior to any specific study procedure.\n2. Must be able to understand the study procedures, comply with them, and give written informed consent prior to any study-specific procedure.\n3. Adult subjects ≥ 18 years of age with a diagnosis of myelodysplastic syndrome.\n4. Very low, low or intermediate IPSS-R risk category.\n5. Subject requires are red blood cell transfusion dependent with the following criteria: requires an average of 2 to 6 units of CH on average over an 8-week period.\n6. ECOG 0-3.\n\nExclusion criteria\n\n1. Subject undergoing any of the following treatments: azacitidine, decitabine, venetoclax, cytotoxic chemotherapy, radiotherapy, arsenic trioxide, interferon or interleukin.\n2. High or very high IPSS-R risk category.\n3. Subject diagnosed with any active neoplasm except:\n\n   * epidermoid or basal cell carcinoma,\n   * carcinoma in situ of the uterine cervix\n   * Carcinoma in situ of the breast\n4. Subjects with a score on the New York Heart Association Scale IV.\n5. Subjects with major surgery within 8 weeks prior to study inclusion. Subjects must have fully recovered from any previous surgery prior to inclusion in the study.\n6. Subject with known clinically significant anaemia due to iron, vitamin B12 or folate deficiencies or autoimmune or hereditary haemolytic anaemia or uncontrolled hypothyroidism or known clinically significant haemorrhage or sequestration or subject with drug induced anaemia.\n7. New onset or uncontrolled seizures.\n8. Subjects with uncontrolled systemic fungal, bacterial or viral infections (defined as ongoing signs or symptoms related to the infection without improvement despite appropriate antibiotics or antimicrobial therapy).\n9. Pregnant or breastfeeding women.\n10. The subject has any condition, including the presence of laboratory abnormalities that would place the subject at unacceptable risk if he\u002Fshe were to participate in the study.\n11. The subject has any condition or receives concomitant medication that confounds the ability to interpret the study data.",{"count":83,"type":20},30,"OBSERVATIONAL","Observational study to evaluate changes in quality of life (QoL) in patients diagnosed with low risk MDS who are red blood cell (abc) transfusion dependent.\n\nChanges in QoL will be correlated with patient cardiorespiratory function. Cardiac biomarkers and plasma cytokines will also be evaluated.",[87],"Low Risk Myelodysplastic Syndromes",[89,90,91],"Myelodysplastic Syndromes","Red blood cell transfusion","Quality of life","2024-09-25",{"date":94,"type":38},"2024-09-27",{"date":96,"type":38},"2024-09-20",{"date":98,"type":20},"2025-12-21",{"name":44,"class":45},""]